Hepatitis C is a Major Global Public Health Problem!
The aims of the Correlation Berlin Hepatitis C Manifesto:
Did dreams come true?
Access to prevention, testing, treatment and care for people who use drugs
Eberhard Schatz, Katrin Schiffer, Mags Maher, Magdalena Harris, Xavier Major Roca,
Mojca Maticic and Astrid Leicht
Urgent action to fight hepatitis C in people
who inject drugs in Europe
John F. Dillon, Jeffrey V. Lazarus and Homie A. Razavi
‘It’s time to change the treatment paradigm:
HCV testing and treatment in community
and low threshold settings’
HVC seminar 3-4 November 2016, Paris, France
In cooperation with the Auto-Support des Usagers de Drogues (ASUD), Association Gaia and the European Network of People Who Use Drugs (EURONPUD), the Correlation Hepatitis C Initiative organised a seminar for community members, harm reduction workers, HCV researchers and activists engaged in HCV prevention, treatment and advocacy. The seminar’s aim was to provide insights in newest developments in HCV testing and treatment opportunities, to present good practices of community and harm reduction based HCV activities and to exchange and discuss future opportunities.
The second day took place in a venue of the first drug consumption room (DCR) in France and highlighted the concept and approach of DCR’s, also on regard of HCV.
The time to foster a unified global response
to the hepatitis C epidemic is now!
- Develop Targeted HCV Strategies and Action Plans
- Provide Access to HCV Testing, Treatment and Care Services
- Scale-up Harm Reduction, evidence and rights and Community-Based Programs
- Decriminalize People Who Use Drugs
- Meaningful inclusion of People who Inject Drugs and their organisations
- Increase Health and HCV Literacy
Hepatitis C among drug users in Europe:
epidemiology, treatment and prevention
EMCDDA, Lisbon, July 2016
EMCDDA published a new INSIGHT report: epidemiology, treatment and prevention provides a timely contribution to raising awareness of the hepatitis C epidemic in Europe and the opportunities now opening up to tackle this problem decisively. A state of the art review of the epidemiology of hepatitis C virus (HCV) infection in Europe and an overview of the way preventive measures are currently implemented in European countries set the scene. International experts address the treatment of HCV infection among people who inject drugs, with an emphasis on how we encourage uptake and deliver effective outcomes. Implementation issues are also explored, as are the complementary roles of treatment and prevention. The new medicines and treatment regimens driving the transformation in the HCV treatment landscape are reviewed in detail. The challenges of scaling up HCV treatment and successfully involving drug using patients is explored from different viewpoints, including that of the drug user.